Only 1 in 10 patients qualify for surgical resection of the pulmonary metastases – thus the management remains a significant clinical challenge. K. Ramadan et al. studied PDT and demonstrated the feasibility and safety of the procedure using 5-ALA and Chlorin e6 drugs with Modulight’s ML6600 laser.
Modulight Spotlights: LASER-SHARP RESEARCH – November 2024 Read More »
Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable
ML7710 for photoactivated treatment of lung cancer Read More »
Several fluorescent agents have been approved for fluorescence based diagnosis & intraoperative imaging: Dye generic name Countries Excitation Detection Indications Indocyanine Green (ICG) Worldwide 800 nm Near-infrared (820 nm) Multiple uses: lymphatic mapping, tissue perfusion, visualization of biliary ducts and blood veins, retinal angiography Fluorescein Worldwide 490 nm Green fluorescence (525 nm) Fluorescein angiography or
Fluorescence imaging & endoscopy for tumor visualization and diagnostics Read More »
Modulight Spotlights: LASER-SHARP RESEARCH – June 2021 Read More »
Published in: British Journal of Cancer Authors: Gal Shafirstein, David A. Bellnier, Emily Oakley, Sasheen Hamilton, Michael Habitzruther, Lawrence Tworek, Alan Hutson, Joseph A. Spernyak, Sandra Sexton, Leslie Curtin, Steven G. Turowski, Hassan Arshad, Barbara Henderson
Treating lung cancer has been a huge challenge, but now, a treatment that’s been around for decades is being used in a new way, and the results so far have been encouraging. In this video thoraic surgeon Dr. Nwogu at Roswell Park Comprehensive Cancer Center explains the benefits of PDT treatment for lung cancer. A
ML7710 for lung cancer treatments at Roswell Park Read More »
Published in: Annals of the American Thoracic Society Authors: Gal Shafirstein 1,2, Athar Battoo 3, Kassem Harris 4, Heinz Baumann 5, Sandra O. Gollnick 1,6, Joerg Lindenmann 1,7, and Chukwumere E. Nwogu 3 1Photodynamic Therapy Center 2Department of Cell Stress Biology 3Department of Thoracic Surgery 4Department of Medicine, Interventional Pulmonology 5Department of Molecular and Cellular Biology, and 6Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York; and 7Division
